Mitsui Chemicals told the Tokyo Stock Exchange on August 17 that it completed its acquisition of Ultradent Products, Inc. on August 14, local time, roughly a month ahead of the September 2026 completion date it had originally flagged. The chemicals group said the earlier close came after the necessary approvals and filings under competition law and foreign investment restriction law were finished faster than it had expected.
The deal itself is not new. Mitsui Chemicals first disclosed the agreement to acquire the US oral-care company on June 12, 2026, then followed on July 14 with notice that it was setting up a new company as part of the transaction structure. This filing is the third and final step in that disclosure chain: confirmation that the purchase has actually closed, not just been agreed.
| Date | Milestone |
|---|---|
| June 12, 2026 | Mitsui Chemicals discloses agreement to acquire Ultradent Products, Inc. |
| July 14, 2026 | Company discloses formation of a new entity tied to the acquisition structure. |
| August 14, 2026 (local time) | Acquisition procedures complete, about a month ahead of the original September 2026 target. |
The more consequential line in the filing is organizational, not transactional. Mitsui Chemicals said the acquisition is the trigger for moving the global headquarters function of its oral-care business from Japan to the US holding company, with the stated aim of maximizing integration effects across the group and building a leading position in oral care. That is a genuine shift in where strategic and operating decisions for the unit get made, not a routine post-merger administrative note; a Japanese industrial conglomerate is relocating command of an entire business line to a US holding company rather than folding Ultradent into existing Japan-based reporting lines.
What the filing does not yet say is how the numbers add up. Mitsui Chemicals said the impact of the acquisition on its consolidated earnings is still under review, and that it will disclose promptly if anything material emerges. Investors get the closing date and the organizational logic; the earnings math, including how Ultradent's revenue and any deal-related charges will show up in group results, is still to come.